CELEX: 62014CA0271
Language: en
Date: 2015-04-16 00:00:00
Title: Joined Cases C-271/14 and C-273/14: Judgment of the Court (Eighth Chamber) of 16 April 2015 (request for a preliminary ruling from the Conseil d’État (France)) — LFB Biomédicaments SA, Association des déficitaires en Alpha 1 Antitrypsine (Association ADAAT Alpha 1-France) (C-271/14), Pierre Fabre Médicament SA (C-273/14) v Ministre des Finances et des Comptes publics, Ministre des Affaires sociales et de la Santé (Reference for a preliminary ruling — Medicinal products for human use — Directive 89/105/EEC — Article 6(3) and (5) — Removal of medicinal products from a list of pharmaceutical proprietary products covered in addition to fixed payments in respect of hospital treatment — Obligation to state reasons)

15.6.2015   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 198/14
            
         Judgment of the Court (Eighth Chamber) of 16 April 2015 (request for a preliminary ruling from the Conseil d’État (France)) — LFB Biomédicaments SA, Association des déficitaires en Alpha 1 Antitrypsine (Association ADAAT Alpha 1-France) (C-271/14), Pierre Fabre Médicament SA (C-273/14) v Ministre des Finances et des Comptes publics, Ministre des Affaires sociales et de la Santé
   (Joined Cases C-271/14 and C-273/14) (1)
   
   ((Reference for a preliminary ruling - Medicinal products for human use - Directive 89/105/EEC - Article 6(3) and (5) - Removal of medicinal products from a list of pharmaceutical proprietary products covered in addition to fixed payments in respect of hospital treatment - Obligation to state reasons))
   (2015/C 198/18)
   Language of the case: French
   
      Referring court
   
   Conseil d’État
   
      Parties to the main proceedings
   
   
      Applicants: LFB Biomédicaments SA, Association des déficitaires en Alpha 1 Antitrypsine (Association ADAAT Alpha 1-France) (C-271/14), Pierre Fabre Médicament SA (C-273/14)
   
      Defendants: Ministre des Finances et des Comptes publics, Ministre des Affaires sociales et de la Santé
   
      Operative part of the judgment
   
   Article 6 of Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems must be interpreted as meaning that the obligation to state reasons provided for in Article 6(3) and (5) is applicable to a decision which restricts the conditions of reimbursement or reduces the level of coverage of a medicinal product by excluding it from the list of proprietary medicinal products covered by compulsory health insurance schemes in addition to services relating to hospital treatment covered by fixed payments in respect of periods of hospitalisation and hospital care.
   
      (1)  OJ C 282, 25.8.2014.